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http://www.biomedcentral.com/1471-244X/13/303RESEARCH ARTICLE Open AccessEvaluating differential developmental trajectories
to adolescent-onset mood and psychotic
disorders
Ian B Hickie1*, Daniel F Hermens1, Sharon L Naismith1, Adam J Guastella1, Nick Glozier1, Jan Scott2,3,4
and Elizabeth M Scott1,5Abstract
Background: It is an open question as to whether differential developmental trajectories, potentially representing
underlying pathophysiological processes, can form the basis of a more useful typology in young persons who
present for mental health care.
Methods: A cohort of 605 young people was recruited from youth mental health services that target the early
phases of anxiety, mood or psychotic disorders. Participants were assigned to one of three clinical sub-types
(anxious-depression; mania-fatigue; developmental-psychotic) according to putative developmental trajectories.
Results: The distribution of subtypes was: 51% anxiety-depression, 25% mania-fatigue and 24% developmental-psychotic,
with key differences in demographic, clinical, family history and neuropsychological characteristics. When analyses were
limited to 286 cases with ‘attenuated’ or sub-threshold syndromes, the pattern of differences was similar. Multinomial
logistic regression demonstrated that compared to the developmental-psychotic subtype, both the mania-fatigue and
anxiety-depression subtypes were younger and more depressed at presentation, but less functionally impaired. Other
discriminating variables between the developmental-psychotic and mania-fatigue sub-types were that the latter were
significantly more likely to have a family history of bipolar disorder but have less likelihood of impaired verbal learning;
whilst the anxious-depression group were more anxious, more likely to have a family history of depression, and had a
higher premorbid IQ level.
Conclusions: This cross-sectional evaluation provides preliminary support for differing developmental trajectories in
young persons presenting for mental health care. Prospective follow-up is needed to examine the predictive validity of
this approach and its relationships to underlying pathophysiological mechanisms.
Keywords: Youth, Neuropsychology, Clinical staging, Sub-syndromal, Phenotype, Illness trajectoryBackground
The optimal meta-structure for differentiation of the major
psychotic, bipolar and unipolar mood disorders for use in
either clinical practice or clinical or related genetic, neuro-
biological or psychological research remains controversial
[1-13]. The failure to resolve these issues may have contrib-
uted significantly to the lack of progress in recent years in
developing new treatments or objective markers of illness
risk, progression or response to treatment [8-13]. Progress* Correspondence: ian.hickie@sydney.edu.au
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stated.in this area may well rely on more novel cross-sectional,
longitudinal or intervention studies that are not simply
limited to cohorts that are restricted to subjects who meet
existing current criteria for caseness or arbitrary diagnos-
tic algorithms that not only demonstrate low reliability
[14] but poor validity [13,15]. While such studies of broad
populations are uncommon in the specialist mental health
literature, they are of considerable relevance not only for
discovery purposes but also to those who provide ongoing
primary or general health care to these more repre-
sentative but less-diagnostically differentiated patient
cohorts [8,9,13,16].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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are better conducted closer to onset of the major disorders,
where confounding factors arising as a result of chronicity,
prolonged exposure to treatments or developments of sec-
ondary morbidities are less important [15,17-21]. When
assessed early in the illness course many symptom clusters
do not yet meet the diagnostic thresholds employed in
current classification systems [16]. As such, the clinical
phenotypes of the early stages of major mood or psychotic
disorders are not easily distinguished and attempting to
classify cases according to conventional diagnostic criteria
and/or predict the illness trajectory may be particularly
unreliable [16,22]. In that context, our own recent studies
have increasingly focused on adolescents and young adults
who present in the early phases of major mental disorders
with admixtures of anxiety, depressive, hypomanic, psych-
otic or substance misuse-related symptoms [13,18].
Researchers have also increasingly highlighted the added
value of incorporating clinical staging alongside traditional
diagnostic formulations, especially for assessing those
initial, less specific clinical presentations that are common
in young people when they first present for specialist care
[15,23-27]. We have established a clinical staging model
that classifies cases according to disease progression from
an asymptomatic, at risk stage (stage 0), to non-specific
clinical presentations (stage 1a) through to more specific,
sub-threshold presentations (stage 1b), and syndromes
meeting diagnostic criteria (stage 2, 3, or 4) [16,28,29].
Although our model is independent of traditional diagnoses
there are several variations of staging models for mental
disorders in use currently (see Cosci and Fava [30]). Other
approaches propose separate models for each major set of
disorders (including schizophrenia, unipolar depression,
bipolar and alcohol use disorders), despite the high
rate of current and lifetime comorbidity between these
conditions. Whilst the clinical staging approach is gaining
acceptance, it may now be apposite also to explore the
utility of employing clinical sub-groupings that more
closely reflect differential developmental, and possibly
underlying pathophysiological, pathways [13].
We have proposed that there are at least three pathways
are common and observable in youth mental health cohorts
[13], and that each can be linked to particular clinical
phenotypes in young people. The proposed pathways, which
may reflect underlying pathophysiological mechanisms,
emphasize neuro-developmental impairments, circadian
dysregulation or heightened sensitivity (i.e. stress-reactivity)
in the ‘fear’ circuitry. We have assigned the following
labels to each clinical phenotype, namely: developmental-
psychotic (DEV-PSY), mania-fatigue (MAN-FAT) and
anxiety-depression (ANX-DEP) sub-types.
Importantly, the DEV-PSYgroup is at the heart of current
research domain criteria (RDoC) initiative proposed by the
NIMH, and is hypothesized to be associated with autism,schizophrenia and/or psychotic phenomena [31-34]. It
is also consistent with other meta-structures that were
proposed for redevelopment of international diagnostic
systems [1,2]. As we hypothesize a different illness tra-
jectory for the DEV-PSY and MAN-FAT subgroups, it is
important to note that any cases with manic like symptoms
(manic, hypomanic or brief hypomanic phenomena)
are preferentially allocated to the MAN-FAT sub-type
irrespective of past or current evidence of psychotic or
other phenomena. Threshold and sub-threshold depressive
syndromes are sub-divided using evidence from ‘prob-
abilistic’ and dimensional models that differentiate be-
tween presentations that are more likely to follow a bipolar
(MAN-FAT) as compared to a unipolar (ANX-DEP) course
[35,36]. We employ the fatigue (FAT) label as the individual
characteristics that most frequently differentiate the
trajectories are the atypical features of depression, especially
reduced activation and energy, and increased need for
sleep, etc. [37-39]. The revised DSM-V criteria recognize
the importance of activation as a cardinal feature of bi-
polarity, which is often a manifestation of underlying
circadian rhythm dysregulation [40,41].
The final (and here residual) sub-type comprises in-
dividuals who frequently reported childhood anxiety,
but later show evidence of heightened stress-sensitivity
and an evolving depressive disorder (but without evidence
of a ‘fatigue’ profile); this is the ANX-DEP sub-type [13].
This most closely reflects the traditional emphasis in
unipolar mood disorders on genetic factors that underpin
stress-sensitivity and early onset anxiety and depressive
disorders [42-46]. Additionally, it encapsulates models
of the neural circuitry of fear responses or glucocorticoid-
dependent arousal and aberrant or prolonged stress re-
sponses [45,47-51]. From a therapeutic perspective, it
emphasizes those depressive disorders that are best
managed by reduction of life-long and predisposing
anxiety – by relevant psychological (e.g. CBT) or pharma-
cological (e.g. SSRIs) interventions.
The first step in testing the validity of these proposed
clinical sub-types is to examine:
(i) Which demographic, clinical, family history,
childhood phenotype, and neuropsychological
characteristics are most strongly associated with
cases allocated to each sub-type;
(ii) If the same patterns of clinical and
neuropsychological characteristics are evident in
cases presenting with a sub-threshold or attenuated
clinical syndrome (i.e. stage 1b); and,
(iii) Which combination of variables best distinguish
between the MAN-FAT, DEV-PSY and ANX-DEP
sub-types after controlling for symptoms and
functional impairment at the time of presentation to
the youth mental health services.
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Participants
With approval from the University of Sydney Human
Research Ethics Committee, consecutive cases presenting
with mood and/or psychotic symptoms to youth mental
health services in and around Sydney were invited to par-
ticipate in a detailed multi-level clinical assessment. Indi-
viduals were included in the study cohort if they: (i) were
willing and able to give written informed consent (or par-
ental consent was obtained e.g. for those aged <16 years);
(ii) presented to the clinical services with sub-threshold
mood and/or psychotic symptoms or with a mood or psych-
otic syndrome; and (iii) agreed to participate in longitudinal
follow-up interviews (including further clinical, sleep, neuro-
psychological and neuro-imaging studies).
Exclusion criteria for all potential participants were:
medical instability or lack of capacity to give informed
consent (as determined by a psychiatrist), history of neuro-
logical disease (e.g. tumor, head trauma, epilepsy), medical
illness known to impact cognitive and brain function
(e.g. cancer, ECT in last 3 months), and/or clinically evident
intellectual and/or developmental disability, and/or in-
sufficient English to participate in the research protocol.
All patients were receiving clinician-based case manage-
ment and relevant psychosocial interventions at the time of
assessment. Additionally, patients who were treated with
psychotropic medications were assessed under ‘treatment
as usual’ conditions, whereby their normal medications
were not altered. At the time of assessment, 27% (163/605)
of patients were not taking psychotropic medications; 44%
(267/605) were taking an anti-depressant; 38% (229/605) an
antipsychotic medication; and 13% (80/605) were taking a
mood stabiliser.
Allocation to clinical sub-types
An independent reviewer (DH) allocated cases to one of the
three proposed sub-groups on the basis of the description
of the clinical presentation alone (i.e. without reference to
any information from the structured research assessment).
Any cases presenting with depressive symptoms only, with
no evidence of psychotic or manic features, and no indica-
tion of atypical symptoms were allocated to the ANX-DEP
group. The reviewer was blinded to all other clinical and
historical information, so cases were excluded (N = 86) from
this cross-sectional study if they could not be allocated to
one of the three sub-types.
Assessment procedure
Structured clinical interviews were undertaken by trained
researchers (psychiatrists, psychologists and neuropsy-
chologists) to establish the following:
a) Demographics and key characteristics: age, gender,
and years of education were recorded. In addition,age at onset of psychiatric symptoms was assessed.
Egeland et al. [52] noted that there are several
definitions that can be used as a proxy measure for age
at onset, but as the assessment is usually retrospective,
all estimates represent approximations and the
definition that is chosen will represent a compromise
between sensitivity and reliability (e.g. personal reports
will usually report earlier age at onset than case records,
but the former may be subject to recall bias and the
latter may under-estimate delays in help seeking). For
the purposes of this study we report age at onset
according to the age at first ever clinical presentation
for treatment of a mental health problem
(which is amenable to independent confirmation).
b) Personal and family history of mental disorders: the
primary clinical diagnosis was assessed using DSM-IV
criteria, and lifetime history of other axis 1 disorders
such as Autistic Spectrum and Attention Deficit
Hyperactivity Disorder (ADHD) were recorded.
Current comorbidities, such as substance misuse
disorder, were also assessed using general questions
supplemented by the 10-item Alcohol Use Disorders
Identification Test (AUDIT; [53,54]). We noted age at
first exposure to, and self-reported use of, nicotine,
cannabis and/or alcohol. Family history of five mental
disorders (anxiety; depression; bipolar; schizophrenia/
schizophreniform; substance/alcohol misuse) and of
suicide was recorded and where possible independent
corroboration was obtained. The assessment
information was also used to determine the clinical
stage of illness (see [13] and [16]). In a small
proportion of cases (5%), clinical stage could not
be accurately assessed, so no rating was assigned.
In this study, cases rated as stage 1b were identified
separately to allow comparison of the characteristics
of attenuated and sub-threshold versus threshold
syndromes (stage 2 and above).
c) Ratings of current symptoms and level of distress:
The interviewer completed the 24-item Brief Psychiatric
Rating Scale (BPRS-24) [55] to quantify general
psychiatric symptoms (this assessment was undertaken
as near as possible to the neuropsychological testing).
Manic symptoms were assessed using the Young Mania
Rating Scale (YMRS; [56]), whilst depressive symptoms
were assessed using the 17-item Hamilton Depression
Rating Scale (HDRS-17) [57], In addition, suicidal
ideation is reported separately as a dichotomy (yes/no).
Psychological distress and fears about general social
interactions (and consequent risk of social avoidance)
were assessed using two established self-ratings: the
Kessler-10 (K-10) [58] and the Social Interaction
Anxiety Scale (SIAS) [59].
d) Social functioning: the clinician completed the
observer-rated social and occupational functioning
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100 with lower scores indicating greater impairment.
e) Neuropsychological profile: premorbid intelligence
(‘predicted IQ’) was estimated on the basis of
performance on the Word Reading subtest of the
Wide Range Achievement Test 4 [61] for those 12
to 15 years old or the Wechsler Test of Adult
Reading [62] for those aged 16 to 30 years old. A
sub-set of neuropsychological tests were then
selected on the basis of their previously established
sensitivity to subtle cognitive changes in young
people with mental disorders [63]. These were:
‘psychomotor speed’, assessed using the Trail-Making
Test, part A (TMT A); ‘mental flexibility’, assessed by
part B (TMT B) [63,64]; ‘verbal learning and
memory’, assessed by the Rey Auditory Verbal
Learning Test (RAVLT) [64] using the sum of trials
RAVLT A1-A5 (learning), and 20-minute delayed
recall by RAVLT A7 (memory).
Statistical analyses
Statistical analyses were performed using SPSS for
Windows 20.0. Cases with missing data were excluded
list-wise from the analyses. All statistical tests were 2-tailed
and used a significance level of α = .01. Group differences
in demographic, clinical and neuropsychological variables
were assessed via ANOVA or chi-square tests where
relevant. Analyses of differences between sub-types were
repeated for a selected sample of cases rated as stage 1b
or stage 2+ (stages 2, 3, or 4). If equality of variance was
compromised (according to Levene’s test) the corrected
degrees of freedom and p-values were reported. To control
for the effects of age, neuropsychological variables were
converted to ‘demographically corrected’ standardized
scores (i.e. z-scores) using established norms for TMT [64]
and RAVLT [65]. Prior to analyses, outliers beyond ± 3.0
z-scores for each neuropsychological variable were curtailed
to values of +3.0 or −3.0 (depending on the direction)
so that the between-group tests were not skewed by
extreme scores [63]. (Outliers across the four variables
comprised <10% of the sample.)
Multi-nomial logistic regression (MNLR) was used to
assess the combination of factors and variables that best
differentiated between clinical subtypes. The DEV-PSY
group was selected as the reference category and the
forward (likelihood ratio) procedure was used for the
regression. Variables were entered into the model if they
had p values lower than 0.01.The variables included in the
model were: gender, age at onset, age at presentation to
youth services, predicted IQ, and ratings on the HDRS,
K-10, SIAS, and SOFAS. Neuropsychological measures
(TMT-A; TMT-B; RAVLT sum score, RAVLTA7) and fam-
ily history of depression, anxiety, bipolar and schizophrenic
disorders all met inclusion criteria. Predictors of sub-groupmembership are reported using B, exp(B), 95% confidence
intervals (95% ci) and significance levels (p values).
The Cox and Snell pseudo R2 statistic is reported as an
indicator of the amount of variance explained by the
regression model.
Results
The study sample comprised of 605 individuals with a mean
age of 19.9 (± 4.3; 12 to 30 years); about 50% (n = 304) were
female. Just over half of the study participants were classified
in the ANX-DEP (51%, n = 310) group, with about a quarter
in either the MAN-FAT (25%; n = 152) or DEV-PSY (24%;
n = 143) groups. While these characteristics closely reflect
the demographics and case mix of the clinical services
from which the cohort was recruited, study participants
demonstrated slightly higher symptom levels [66].
As shown in Table 1, the DEV-PSY sub-group is predom-
inantly male and is older at presentation to youth mental
health services and at first ever contact with clinical services
than the other groups. Although the overall level of psychi-
atric symptoms (as measured on the BPRS) is similar to
other groups, the DEV-PSY group had less severe clinician-
rated depressive symptoms (HDRS), lower levels of suicidal
ideation and lower self-rated levels of social anxiety (SIAS)
or distress (K-10). There were no between group differences
in education level, but the DEV-PSY group had a signifi-
cantly lower premorbid IQ (reflected by predicted IQ)
and a lower level of clinician-rated social and occupational
functioning (SOFAS).
As shown in Table 2, neuropsychological testing demon-
strated significant group differences in processing speed,
mental flexibility, and verbal learning and memory tasks.
For each assessment, the DEV-PSY group performed poorly
as compared to the ANX-DEP and MAN-FAT groups
(who were very similar to each other). Deficits in the DEV-
PSY group were particularly marked for tests of mental
flexibility and verbal learning and memory (z-score <−1.0).
About half of study participants (286 of the 575 with a
clinical stage assigned) were rated as being at stage 1b at
the time of assessment; a significantly higher proportion
of cases in the ANX-DEP (n = 174; 56%) and MAN-FAT
(n = 82; 53%) groups were regarded as presenting with
sub-threshold syndromes compared to the DEV-PSY group
(n = 28; 20%) (X2 = 56.2; df = 2; p < 0.001). Comparison of
clinical and neuropsychological profiles between cases
rated as stage 1b compared to stage 2+ suggested that
between group differences were evident for stage 1b
cases with regards to age at presentation, age at first
treatment, years in education and predicted IQ; im-
pairments in functioning and general behavioral dis-
turbance were less marked in the stage 1b compared to
stage 2, but the pattern of differences was consistent. There
were marginal changes in gender distribution (Female:
ANX-DEP = 58%; MAN-FAT = 72%; DEV-PSY = 29%),
Table 1 Demographic and clinical profile of cases classified as: (i) ‘anxious-depression’ (ANX-DEP); (ii) ‘mania-fatigue’
(MAN-FAT); or (iii) ‘developmental-psychotic’ (DEV-PSY)
ANX-DEP
(n = 310)
MAN-FAT
(n = 152)
DEV-PSY
(n = 143)
Significance test
χ2 or ANOVA (2, df) [p]
Female, % (n) 53.0% (n = 165) 66.4% (n = 101) 25.9% (n = 37) χ2 (605) = 50.2 [.000]
Age in yrs (Mean ± SD) 19.2 ± 4.3 20.2 ± 4.0 21.1 ± 4.6 F (604) = 10.7 [.000]
Age at 1st treatment, in yrs 14.5 ± 4.3 14.4 ± 3.5 17.5 ± 5.4 F (251.8) = 15.8 [.000]
Education, in yrs 11.4 ± 2.8 11.9 ± 2.4 11.5 ± 2.6 F (549) = 2.2 [.112]
Predicted IQ 103.0 ± 10.3 101.4 ± 10.2 97.1 ± 12.1 F (500) = 12.1 [.000]
BPRS total 39.7 ± 10.0 41.0 ± 10.1 39.4 ± 10.6 F (536) = 1.1 [.333]
HDRS total 12.4 ± 6.8 12.1 ± 6.9 8.8 ± 5.9 F (275.9) = 14.7 [.000]
YMRS 3.1 ± 4.4 6.8 ± 8.6 2.4 ± 3.7 χ2 (264) = 10.4# [0.005]
Suicidal ideation 38.7% (105/271) 35.2% (50/142) 20.2% (26/129) χ2 (542) = 13.9 [.001]
Distress (K-10 total) 27.3 ± 7.7 27.2 ± 8.4 22.8 ± 8.7 F (486) = 12.7 [.000]
Social anxiety (SIAS total) 39.0 ± 16.6 33.8 ± 18.4 31.8 ± 15.9 F (436) = 7.8 [.000]
SOFAS 60.4 ± 11.6 61.4 ± 11.5 56.3 ± 12.3 F (553) = 7.6 [.001]
Note: SOFAS = Social and Occupational Functioning Assessment Scale; HDRS = Hamilton Depression Rating Scale; BPRS = Brief Psychiatric Rating Scale;
K-10 = Kessler-10; SIAS = Social Interaction Anxiety Scale; YMRS = Young Mania Rating Scale; #Kruksal Wallis test.
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MAN-FAT = 12.6; DEV-PSY = 9.6), and distress levels
(mean K-10: ANX-DEP = 27.9; MAN-FAT = 28.5;
DEV-PSY = 23.9). The pattern of significant neuro-
psychological differences remained the same, although
the overall levels of impairments were less marked in the
stage 1b compared to stage 2+ in the DEV-PSY group
(data available from the corresponding author).
As shown in Table 3, there was a significant difference
(p < .05) among the tripartite sub groups in the proportion
of patients who were not taking any psychotropic medica-
tions at the time of assessment with the ANX-DEP group
having the highest proportion (i.e. 31%). Chi-square tests
also revealed highly significant differences among the sub-
groups in the proportions of patients who were taking any
anti-depressant, any anti-psychotic and any mood stabiliser
(see Table 3). Approximately half of the ANX-DEP and
MAN-FAT groups were taking any anti-depressant medica-
tion compared to only one-quarter of the DEV-PSY group.
In terms of any anti-psychotic use, the MAN-FAT and
DEV-PSY groups were two to three times more likely toTable 2 Neuropsychological profile of cases classified as: (i) ‘a
(MAN-FAT); or (iii) ‘developmental-psychotic’ (DEV-PSY)
Mean z-scores
(± standard deviation)
ANX-DEP
(n = 310)
MA
(n
Psychomotor speed (TMT-A) 0.0 ± 1.0 0.
Mental flexibility (TMT-B) −0.5 ± 1.3 −0
Verbal learning (RAVLT sum) −0.2 ± 1.3 −0
Verbal memory (RAVLT A7) −0.1 ± 1.2 −0be taking this medication compared with those in the
ANX-DEP group (at 22%). While less than 10% of the both
the ANX-DEP and DEV-PSY groups were currently taking
any mood stabiliser, more than 30% of the MAN-FAT sub-
group were.
The assessment of co-morbidities demonstrates that
the DEV-PSY sub-group reported higher rates of ADHD
(see Table 4), but there were no between group differences
in reported rates of autistic spectrum disorders. Comorbid
alcohol and other substance misuse rates were comparable
across all groups (37-44%) as were the rates of nicotine,
cannabis and alcohol use. The mean ages at first use
(14–15 years) were similar across sub-types.
For family history (see Table 4), the overall patterns of
differences in rates of specific disorders suggested im-
portant distinctions between the sub-types. Specifically,
the DEV-PSY group reported the lowest familial rates of
depression (24%) and highest rates of schizophrenia/
schizophreniform disorders (23%), while those in the
MAN-FAT group reported the highest rates of anxiety
(34%) and bipolar disorder (28%). The ANX-DEP groupnxious-depression’ (ANX-DEP); (ii) ‘mania-fatigue’
N-FAT
= 152)
DEV-PSY
(n = 143)
Significance test
ANOVA (2, df) [p]
1 ± 1.0 −0.4 ± 1.0 F (517) = 7.1 [.001]
.4 ± 1.3 −0.8 ± 1.3 F (512) = 3.6 [.029]
.1 ± 1.2 −1.1 ± 1.3 F (514) = 26.2 [.000]
.3 ± 1.3 −1.0 ± 1.3 F (513) = 23.9 [.000]
Table 3 Cross-tabulation of subgroup (i.e. ‘anxious-depression’ (ANX-DEP); ‘mania-fatigue’ (MAN-FAT);
‘developmental-psychotic’ (DEV-PSY)) by medication status
Current medication ANX-DEP (n = 310) MAN-FAT (n = 152) DEV-PSY (n = 143) Significance test
NIL
Count 97 31 35
χ2 (2, 605) = 6.6 [.037]
% 31.2% 20.3% 24.5%
Any anti-depressant
Count 158 71 38
χ2 (2, 605) = 23.9 [.000]
% 50.8% 46.7% 26.6%
Any anti-psychotic
Count 68 74 87
χ2 (2, 605) = 73.5 [.000]
% 21.9% 48.7% 60.8%
Any mood stabilizer
Count 19 49 12
χ2 (2, 605) = 64.6 [.000]
% 6.1 32.2 8.4
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history of substance/alcohol misuse disorders and suicide
were similar across subtypes.
As shown in Table 5, the multinomial logistic regression
analysis demonstrated that the model that significantly
differentiated between the groups (X2 = 133.89; df = 30;
p < 0.001; Cox and Snell pseudo R2 = 0.39) included the
following: age at presentation, HDRS, SOFAS, SIAS, family
history of depression and bipolar disorder, and verbal learn-
ing, (with predicted IQ and family history of schizophrenia
associated with p values of 0.054 and 0.058, respectively).
The DEV-PSY subtype differed from both the MAN-FAT
and the ANX-DEP groups on age at presentation to youth
mental health services (DEV-PSY older), HDRS scores
(less depressed) and SOFAS scores (more impaired). Fur-
thermore, DEV-PSY cases were more likely than MAN-FATTable 4 Prevalence of comorbid diagnoses (top panel) and po
(i) ‘anxious-depression’ (ANX-DEP); (ii) ‘mania-fatigue’ (MAN-F
ANX-DEP MA
(n = 310) (n
Comorbidity
ADHD 13% (40/310) 11%
Autistic spectrum disorders 7% (20/310) 3%
Substance use
Comorbid substance misuse 37% (115/310) 44%
Age first nicotine [% cases = users] 14.8 ± 2.5 [56%] 14.
Age first alcohol [% cases = users] 14.7 ± 2.4 [78%] 14.
Age first cannabis [% cases = users] 15.6 ± 2.3 [50%] 15.
Family History
Depression (n/N) 56% (129/231) 54%
Anxiety (n/N) 22% (51/231) 34%
Bipolar (n/N) 12% (27/231) 28%
Schizophrenia (n/N) 7% (17/231) 18%
Substance misuse (n/N) 21% (49/231) 30%
Suicide (n/N) 6% (15/231) 4%
Note: ‘ADHD’ = Attention Deficit Hyperactivity Disorder.cases to show impaired verbal learning (RAVLT sum score)
and less likely to have a family history of bipolar disorders.
Compared to the ANX-DEP, the DEV-PSY group were less
anxious (SIAS), less likely to have a family history of depres-
sion, and more likely to have a lower predicted IQ level.
Discussion
Before discussing the findings in detail, it is useful to high-
light two issues. First, this cohort of young people has sig-
nificant levels of symptoms, functional impairment, distress
and suicidal ideation that warrant clinical intervention; and
that this need for care and treatment is apparent whether
or not the presenting symptoms reached current thresholds
for diagnostic caseness [66-68]. Second, this study attempts
to avoid one of the commonest problems encountered
in assessing the clinical, familial and neuropsychologicalsitive family history (bottom panel) of cases classified as:
AT); or (iii) ‘developmental-psychotic’ (DEV-PSY)
N-FAT DEV-PSY Significance test
= 152) (n = 143) χ2 or ANOVA(2,df) [p]
(17/152) 24% (34/143) 12.4 [.015]
(5/152) 6% (8/143) 2.0 [.371]
(67/152) 41% (59/143) 2.3 [.313]
6 ± 3.1 [67%] 14.8 ± 2.8 [69%] F (291) = 0.2 [.850]
4 ± 2.2 [87%] 14.6 ± 3.3 [79%] F (181.5) = 0.4 [.642]
3 ± 2.7 [60%] 15.3 ± 2.4 [56%] F (260) = 0.4 [.674]
(65/120) 24% (27/112) 33.1 [.000]
(41/120) 14% (16/112) 13.2 [.001]
(34/120) 7% (8/112) 24.3 [.000]
(22/120) 23% (26/112) 18.2 [.000]
(36/120) 25% (28/112) 3.3 [.189]
(5/120) 6% (7/112) 0.8 [.672]
Table 5 Multinomial logistic regression analysis of characteristics that best discriminate cases classified as: (i)
‘anxious-depression’ (ANX-DEP) or (ii) ‘mania-fatigue’ (MAN-FAT) compared to ‘developmental-psychotic’ (DEV-PSY)
B Sig. Exp
(B)
95% Confidence
Intervals for Exp (B)
MAN-FAT
Age at presentation -.22 .001 .80 .70 .92
SOFAS .05 .04 1.05 1.01 1.09
HDRS .12 .01 1.13 1.03 1.24
No family history of bipolar disorder# −1.47 .03 .23 .06 .84
RAVLT sum score .61 .04 1.85 1.04 3.29
ANX-DEP
Age at presentation -.16 .01 .85 .76 .95
SOFA .052 .01 1.05 1.02 1.09
HDRS .105 .02 1.11 1.02 1.21
SIAS .038 .01 1.04 1.01 1.07
No family history of deppression# −1.16 .01 .31 .13 .76
Predicted IQ .046 .03 1.05 1.00 1.09
Note: Exp (B) > 1.0 indicates higher; Exp (B) < 1.0 indicates lower.
# a negative value for B and an odds ratio (Exp (B)) <1.0 indicates lower proportions for the factor e.g.
‘No Family History’ indicates that the group is more likely to have a positive family history.
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namely the over-reliance on positive DSM or ICD-like
‘case’ versus normal ‘control’ strategies. Comparing a single
diagnostic subgroup with a non-clinical, ‘healthy’ con-
trol group is of limited value when the ultimate goal is
to identify the characteristics that best discriminate be-
tween clinical syndromes and/or will predict the future
illness trajectories of young people who present for
care. Also, a simple case–control approach will not help
in attempts to identify biomarkers of transition from
sub-threshold disorders to full-syndrome disorders, nor of
future homotypic or heterotypic disease progression. As
clinicians increasingly attempt the early identification and
treatment of young people presenting in the initial stages of
mental disorder (typically stage 1b or stage 2), it is likely that
studies utilizing ‘positive case-positive control’ designs
(i.e. case versus case) will become increasingly important [16].
In this study we examine the similarities and differences
between three putative developmental trajectories that
lead to adolescent-onset disorders – namely, ANX-DEP,
MAN-FAT, and DEV-PSY disorders. These sub-types
draw, in part, on historical distinctions between depressive
disorders driven by heightened sensitivity to environmental
stressors thresholds, circadian-based mood disorders
(including bipolar spectrum and atypical depression
syndromes) and psychotic disorders with or without
affective components (broadly defined and often linked
to evidence of earlier deviations in brain development).
The study also seeks to apply these concepts to young
people with attenuated syndromes before the symptoms
progress to classical, more easily distinguished, or morestable syndromes. As such, this tripartite model builds
on established diagnostic categories, extending them
to sub-threshold presentations via the use of a clinical
staging framework, and further refining them by classifying
cases on the basis of a putative clinical phenotype
linked to a proposed underlying pathophysiology and
illness trajectory. However, it differs from other histor-
ical approaches to classifications that have traditionally
given more weight to psychotic symptoms - because these
were perceived as most relevant to diagnostic hierarchies
[4,13,69]. Our approach is supported by contemporary
evidence that increasingly emphasizes the importance of
developmental psychopathology and highlights the key role
of anxiety and depression in the evolution of most adult
prototype severe mental disorders and offers a rationale
for giving greater priority to these symptoms [22,33,70].
The differential demographic (older, more male popula-
tion in the DEV-PSY subgroup), developmental (lower IQ
and higher rate of diagnosed ADHD in the DEV-PSY
subgroup), and phenotypic (more severe depression,
suicidal ideation and anxious features in the ANX-DEP
and MAN-FAT subgroups; more social avoidance in the
ANX-DEP subgroup) characteristics are consistent with the
findings of other longitudinal, clinical and epidemio-
logical studies and lend support to the proposed model
of sub-types [15,31-34,40,41,70,71]. Further, when we
limited the analyses to cases with early or ‘attenuated’
or sub-threshold syndromes only, these differential
patterns were for the most part preserved, suggesting
that they potentially represent important discriminating
features. Other characteristics, such as education, general
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substance misuse disorders (which have been reported
to be associated with onset of psychosis or severe mood
disorders when examined in case–control studies), did
not discriminate between the three sub-groups, again
supporting the findings from studies that employ positive
case-case designs. Whilst some between group differences
may have been influenced by the reasons for presentation
to youth mental health services (e.g. DEV-PSY may present
because of concerns regarding impaired level of function-
ing; ANX-DEP may present because of levels of distress),
the proposed sub-types were also differentiated on the
basis of family history of mental disorders and neuro-
psychological testing. This is important as these are widely
regarded as two of the most robust and frequently utilized
cross-sectional strategies currently available to test the val-
idity of proposed clinical sub-groups [34,43,63,71].
The patterns of neuropsychological impairment strongly
differentiated the DEV-PSY group from the mood sub-
types, particularly with regards to verbal learning and
memory, and to a lesser extent to processing speed. These
profiles are consistent with other neuropsychological
studies in young people across the mood disorders and
psychosis spectrum [34,63]. The differences may be partly
explained by the fact that the DEV-PSY group had fewer
cases classified as sub-syndromal (stage 1b) and a signifi-
cantly lower mean IQ. However, the difference in verbal
learning remained significant in the multinomial regres-
sion when other factors were taken into account and this
abnormality has been reported as a key difference between
individuals at high risk of psychosis who do not make
the transition to illness compared to those who make
the transition to psychosis (e.g. [72]). The findings are
also consistent with structural brain imaging studies in
young persons with similar phenotypic characteristics
that suggest greater temporal lobe changes in those
with psychotic features (as compared with frontal lobe
features that appear to be common across the mood
disorder and psychotic spectrum) [31,38,72].
Finally, it is important to acknowledge some important
study limitations. First, the cohort represents a sub-sample
of referrals to youth mental health services and biases
in referral processes and/or the exclusion of cases that
could not be classified could have influenced our find-
ings. Although we have evidence that the sample re-
flects the case mix in the clinical service, we cannot
rule out biases entirely, so replication of the study is
necessary [66-68]. It is also worth noting, however, that
this study was not designed to test the viability of such
a differential developmental model in the general
population. Second, the small proportion of DEV-PSY
cases rated as stage 1b means some of the analyses may
be less reliable for this sub-group. Clearly, studies with
much larger sample sizes are needed to address thisissue, particularly with respect to positive case-positive
control designs where the it is important to have a
good representative of both ‘sub-syndromal’ and ‘full-
threshold’ subjects who may have differing interpreta-
tions of their own early stages of illness. Third, in order
to maximize participation in the study, we limited the
assessment of some aspects of the developmental and
illness history, so again this may have implications for
the delineation of clinical subtypes [18]. Fourth, we did
not analyze treatment patterns (as we do not use this
to define/confirm the groups), but these may of course
have modified the current level of reported symptoms
or impacted on neuropsychological tests. The extent to
which medication use may also lead to misattribution
of sub-type is difficult to determine empirically. However,
it is possible that a small number of cases who would
otherwise be allocated to the MAN-FAT or DEV-PSY
group were assigned to the default ANX-DEP. It is notable
that, as individuals were assessed at the time of presenta-
tion to the youth services, the majority of cases were not in
receipt of long term and/or high dosages of antipsychotic,
antidepressant or mood-stabilizing medications. Finally, this
report is only the first step in the development of the tripar-
tite sub-type model. The present study was reliant largely
on cross-sectional comparisons of key phenotypic, clinical
and neurocognitive characteristics. Furthermore, this
study had relatively large subgroup sizes and therefore
the functional and/or clinical relevance of key measures
(e.g. significant predictors with narrow confidence intervals)
need to be further evaluated. Future studies may benefit
from the exploration of other factors, such as early life
trauma, social support and/or metacognitive capacities
to differentiate these subgroups. Such measures may help
explain, for example, why the DEV-PSY group reported
lower levels of depressive symptomatology compared to
the other groups. It is possible this subgroup of subjects
express their distress differently or have an altered cap-
acity to articulate mood or other emotional symptoms.
Clearly the next major step is to follow this cohort pro-
spectively. This will allow us to examine the longitu-
dinal characteristics of the model, to test its capacity to
predict course of illness, and to examine any differential
responses to personalized treatments selected on the
basis of the proposed underlying pathophysiology and
developmental trajectories.
Conclusions
This cross-sectional study of 605 young people presenting
for mental health care provides provisional support for a
model that differentiates subjects into three subgroups
(anxious-depression, mania-fatigue, developmental-psychotic)
based largely on differential childhood and adolescent tra-
jectories.While the model shares key concepts with more
traditional contrasts between psychotic and non-psychotic
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order types based largely on changes in motor or psychic
activation or the presence of prior or concurrent anxiety.
While this tripartite model is supported by key differences
in clinical, family history and neuropsychological character-
istics, relevant prospective and comparative intervention
studies are now required to test its predictive validity.
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